As previously reported by NutraIngredients-USA, the SIMBA capsule, a noninvasive ingestible device, gathers fluid samples from the small intestine, enabling researchers to explore metabolite production and microbial activity.
It provides a direct approach to microbiota samples compared with fecal or endoscopic samples by gathering information that can help create precise interventions and targeted therapies for people suffering from conditions such as small intestinal bacterial overgrowth (SIBO).
This innovative technology led to Nimble being named NutraIngredient’s Start-up of the Year in 2024.
“The ability to interrogate the small intestine directly, with endoscopy-quality, scalable data collected via our simple home-use capsule kits has been transformative for our customers,” Sabina Bruehlmann, CEO of Nimble Science, said in the press release. “Partnering with Cmbio allows them to integrate this data into the most advanced multi-omics platforms available today. Together, we are advancing microbiome research and personalized medicine.”
‘An important step’
Cmbio will take on the role of certified service provider, supplying insights into Nimble’s data such as identifying microbiota-driven mechanisms that impact immune modulation, metabolic pathways and nutrient absorption.
“This collaboration marks an important step in our mission to decode the microbiome’s role in health and disease,” said Anders Grøn, CEO of Cmbio. “By incorporating Nimble’s innovative data platform into our multi-omics services, we can now offer our clients access to previously unreachable data from the small intestine.”
In addition, the research from the SIMBA technology could help pharmaceutical companies develop better, more effective medications for conditions such as IBS, as well as dietary interventions and live biotherapeutics.
Eagle Genomics
Also in January, Cmbio announced it had acquired the “e[datascientist]” software platform through an Asset Sale Agreement with CBW Recovery LLP and Eagle Genomics Limited, which went into administration during the summer of 2024.
“With the addition of the Eagle Genomics platform, we continue to expand on Cmbio’s unique technology suite built on decades of expertise in multi-omics science,” said Manoj Dadlani, chairman of Cmbio.
“This acquisition reflects our ongoing strategy to add complementary technologies that strengthen our position as the preferred partner within multi-omics services worldwide.”
